Literature DB >> 19896595

Efficacy of bipolar radiofrequency endometrial ablation vs thermal balloon ablation for management of menorrhagia: A population-based cohort.

Sherif A El-Nashar1, Matthew R Hopkins, Douglas J Creedon, William A Cliby, Abimbola O Famuyide.   

Abstract

STUDY
OBJECTIVE: To compare the efficacy of bipolar radiofrequency ablation (RFA) and thermal balloon ablation (TBA) using treatment failure and postprocedure amenorrhea as outcome measures.
DESIGN: Population-based cohort study (Canadian Task Force classification II-2).
SETTING: Two medical centers in the upper Midwest. PATIENTS: Using the medical records linkage system of the Rochester Epidemiology Project, we identified 455 residents of Olmsted County, Minnesota, who underwent global endometrial ablation because of menorrhagia from January 1, 1998, through December 31, 2005. Amenorrhea was defined as complete cessation of menstruation that started immediately after ablation and lasted at least 12 months. Treatment failure was defined as necessity of repeat ablation or hysterectomy because of persistent bleeding or pain. Time to treatment failure for each procedure was compared using Kaplan-Meier plots. Relevant clinical data and complications were abstracted from medical records. Risk adjustments were performed using Cox and logistic regression models.
INTERVENTIONS: Radiofrequency ablation (n=255) and thermal balloon ablation (n=200).
MEASUREMENTS AND MAIN RESULTS: Mean (SD) patient age was 43.3 (5.5) years, and median follow-up was 2.2 years. The 3-year cumulative failure rate was 9% (95% confidence interval [CI], 5%-16%) for RFA and 12% (95% CI, 7%-16%) for TBA (p=.26). The difference remained nonsignificant after adjusting for known predictors of treatment failure such as age, parity, pretreatment dysmenorrhea, and tubal ligation (adjusted HR, 0.7; 95% CI, 0.4-1.4; p=.31). However, women had significantly higher rates of amenorrhea after RFA compared with TBA (32% vs 14%; p <.001). This difference remained significant after adjusting for known predictors of amenorrhea such as age, uterine length, and endometrial thickness (adjusted odds ratio, 2.9; 95% CI, 1.7-4.8; p <.001). Complications were infrequent and similar in the 2 groups.
CONCLUSION: Both RFA and TBA were equally effective treatments for menorrhagia in a population-based cohort. However, women who underwent RFA were 3 times more likely to have postprocedure amenorrhea.

Entities:  

Mesh:

Year:  2009        PMID: 19896595      PMCID: PMC3770134          DOI: 10.1016/j.jmig.2009.06.022

Source DB:  PubMed          Journal:  J Minim Invasive Gynecol        ISSN: 1553-4650            Impact factor:   4.137


  26 in total

Review 1.  Hysteroscopic and nonhysteroscopic endometrial ablation.

Authors:  George A Vilos
Journal:  Obstet Gynecol Clin North Am       Date:  2004-09       Impact factor: 2.844

Review 2.  Menorrhagia: a review.

Authors:  M A Van Eijkeren; G C Christiaens; J J Sixma; A A Haspels
Journal:  Obstet Gynecol Surv       Date:  1989-06       Impact factor: 2.347

3.  Prognostic factors for success of endometrial ablation and resection.

Authors:  D E Parkin
Journal:  Lancet       Date:  1998-04-18       Impact factor: 79.321

4.  Sources of variation in menstrual blood loss.

Authors:  S K Cole; W Z Billewicz; A M Thomson
Journal:  J Obstet Gynaecol Br Commonw       Date:  1971-10

5.  An investigation in primary care of the relationship between consultation behaviour, increased vaginal bleeding and mental disorder.

Authors:  M Shapley; K Jordan; P R Croft
Journal:  J Obstet Gynaecol       Date:  2004-09       Impact factor: 1.246

6.  History of the Rochester Epidemiology Project.

Authors:  L J Melton
Journal:  Mayo Clin Proc       Date:  1996-03       Impact factor: 7.616

7.  The measurement of observer agreement for categorical data.

Authors:  J R Landis; G G Koch
Journal:  Biometrics       Date:  1977-03       Impact factor: 2.571

Review 8.  Endometrial destruction techniques for heavy menstrual bleeding.

Authors:  A Lethaby; M Hickey; R Garry
Journal:  Cochrane Database Syst Rev       Date:  2005-10-19

9.  Randomised controlled trial of bipolar radio-frequency endometrial ablation and balloon endometrial ablation.

Authors:  Marlies Y Bongers; Petra Bourdrez; Ben W J Mol; A Peter M Heintz; Hans A M Brölmann
Journal:  BJOG       Date:  2004-10       Impact factor: 6.531

10.  The endometrial ablator: a new instrument.

Authors:  R S Neuwirth; A A Duran; A Singer; R MacDonald; L Bolduc
Journal:  Obstet Gynecol       Date:  1994-05       Impact factor: 7.661

View more
  6 in total

Review 1.  Challenges in the gynecologic care of premenopausal women with breast cancer.

Authors:  Jamie N Bakkum-Gamez; Shannon K Laughlin; Jani R Jensen; Clement O Akogyeram; Sandhya Pruthi
Journal:  Mayo Clin Proc       Date:  2011-02-09       Impact factor: 7.616

2.  Decreased expression of survivin, estrogen and progesterone receptors in endometrial tissues after radiofrequency treatment of dysfunctional uterine bleeding.

Authors:  Geping Yin; Tongyu Zhu; Juan Li; Ming Chen; Shujun Yang; Xiaoli Zhao
Journal:  World J Surg Oncol       Date:  2012-06-01       Impact factor: 2.754

3.  Cost effectiveness of endometrial ablation with the NovaSure(®) system versus other global ablation modalities and hysterectomy for treatment of abnormal uterine bleeding: US commercial and Medicaid payer perspectives.

Authors:  Jeffrey D Miller; Gregory M Lenhart; Machaon M Bonafede; Cindy M Basinski; Andrea S Lukes; Kathleen A Troeger
Journal:  Int J Womens Health       Date:  2015-01-06

4.  Incidence and predictors of failed second-generation endometrial ablation.

Authors:  Jordan Klebanoff; Gretchen E Makai; Nima R Patel; Matthew K Hoffman
Journal:  Gynecol Surg       Date:  2017-12-15

5.  Endometrial resection and ablation techniques for heavy menstrual bleeding.

Authors:  Magdalena Bofill Rodriguez; Anne Lethaby; Mihaela Grigore; Julie Brown; Martha Hickey; Cindy Farquhar
Journal:  Cochrane Database Syst Rev       Date:  2019-01-22

6.  CavatermTM plus treatment in high - risk surgical patients.

Authors:  Zinatossadat Bouzari; Ebrahim Alijanpour; Shahla Yazdani; Azita Ghanbarpour; Ali Bijani; Tahereh Ashraf Ganjoei; Hemmat Gholinia
Journal:  Caspian J Intern Med       Date:  2021-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.